Skip to main content
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Industry Experts
Loading
Christilyn Graff
Senior Vice President, Head of Research,
Mosaic Biosciences
Sessions
19-Feb-2025
11:20– 12:20
Which are the best approaches to overcome lower affinity for target specificity and efficacy
LinkedIn
YouTube
Search
Search
Search
Username *
Password *
Login
)
